Brought to you by 
Acton licenses Forest's FDA-approved Aerospan
27 Oct 2020
Executive Summary
The same day it closed its $15mm Series A round, Acton Pharmaceuticals (respiratory therapeutics) announced its first alliance. The company licensed exclusive US rights to Forest Laboratories' Aerospan (flunisolide HFA 80mcg), an FDA-approved inhaled corticosteroid (ICS) for asthma.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acton licenses Forest's FDA-approved Aerospan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice